Inovio Receives Advanced Therapy Medicinal Product Certificate From EMA For Quality And Non-Clinical Data For Lead Candidate INO-3107
Portfolio Pulse from Benzinga Newsdesk
INOVIO (NASDAQ:INO) has received an Advanced Therapy Medicinal Product Certificate from the European Medicines Agency for its lead candidate INO-3107, confirming compliance with standards for a potential EU Marketing Authorization Application.
July 25, 2024 | 8:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
INOVIO has received an Advanced Therapy Medicinal Product Certificate from the European Medicines Agency for its lead candidate INO-3107, confirming compliance with standards for a potential EU Marketing Authorization Application.
The certification from the EMA is a significant milestone for INOVIO, as it confirms that their lead candidate INO-3107 meets the necessary scientific and technical standards for a potential EU Marketing Authorization Application. This could positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100